Compare CX & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CX | NBIX |
|---|---|---|
| Founded | 1906 | 1992 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 15.5B |
| IPO Year | 2000 | 1996 |
| Metric | CX | NBIX |
|---|---|---|
| Price | $10.19 | $150.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $12.21 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 5.0M | 949.8K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $8.28 | $24.73 |
| Revenue Next Year | $4.34 | $13.14 |
| P/E Ratio | ★ $19.03 | $47.34 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $8.73 | $122.14 |
| 52 Week High | $13.67 | $186.12 |
| Indicator | CX | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 52.22 |
| Support Level | $10.46 | $152.67 |
| Resistance Level | $13.30 | $161.00 |
| Average True Range (ATR) | 0.23 | 4.14 |
| MACD | 0.02 | 0.85 |
| Stochastic Oscillator | 6.05 | 84.92 |
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.